Hereditary Angioedema Therapeutic Market Overview
The global hereditary angioedema (HAE) therapeutic market was valued at approximately USD 3.16 billion in 2024 and is expected to grow at a CAGR of 7.80% during the forecast period 2025-2034, reaching a market value of around USD 6.70 billion by 2034. Hereditary angioedema is a rare genetic disorder characterized by recurrent swelling attacks affecting various body parts including the face, extremities, and airways, which can be life-threatening. The rising awareness, better diagnosis, and the availability of advanced treatment options are fueling market growth globally.
Market Segmentation by Drug Class
C1-Esterase Inhibitor: The dominant drug class used both for acute attack treatment and prophylaxis, leveraging its proven efficacy in regulating the complement system and preventing swelling episodes.
Bradykinin B2 Receptor Antagonist: Provides symptom relief by blocking bradykinin receptors responsible for vascular permeability, mainly used for on-demand treatment during acute attacks.
Kallikrein Inhibitor: Emerging class playing a crucial role in both prophylactic and on-demand therapies by inhibiting kallikrein, a key enzyme in the HAE pathway.
Others: Include adjunctive therapies and newer biologics under development aimed at improved efficacy and patient compliance.
Market Segmentation by Treatment Type
Prophylaxis Treatment: Growing rapidly as patients increasingly adopt preventive therapies to reduce attack frequency and improve quality of life.
On-Demand Treatment: Used for immediate relief during acute HAE attacks; continues to hold a significant share due to unpredictable attack nature.
Route of Administration Breakdown
Intravenous: Historically the most common administration route, especially for C1-Esterase inhibitors.
Subcutaneous: Increasingly preferred for its convenience and patient compliance, with several new formulations approved in recent years.
Oral: An emerging and highly convenient route, with newer oral kallikrein inhibitors and receptor antagonists expected to drive market growth substantially.
Regional Market Insights
North America: Largest market share powered by high disease awareness, advanced healthcare infrastructure, and early access to innovative therapies. The U.S. leads due to strong clinical networks and patient advocacy.
Europe: Significant market presence driven by increasing diagnostic rates and adoption of prophylactic therapies.
Asia Pacific: Fastest growing region fueled by rising awareness, improving healthcare access, and regulatory support for orphan drugs.
Latin America and Middle East & Africa: Emerging markets with growing diagnostic capabilities and increasing treatment availability.
Market Drivers and Growth Opportunities
Rising incidence and improved diagnosis rates owing to advances in genetic testing and better clinical awareness among healthcare providers.
Increasing adoption of prophylactic therapies to prevent debilitating and life-threatening HAE attacks.
Development of patient-friendly therapies such as subcutaneous and oral administration improving treatment adherence and quality of life.
Expansion of patient support programs and health policies supporting orphan drug access.
Strategic collaborations and pipeline innovations, including novel biologics and small molecule therapies addressing unmet clinical needs.
Challenges and Market Restraints
High cost of HAE therapies limits accessibility, especially in low- and middle-income countries, and poses payer challenges.
Delayed or misdiagnosis due to rarity and symptom similarity to other conditions restricts diagnosed patient population.
Safety concerns for long-term treatment options, including risks of thrombosis related to some therapies.
Stringent regulatory pathways for new drug approvals and orphan drug designations can cause delays.
Leading Companies in the Hereditary Angioedema Therapeutic Market
Takeda Pharmaceutical Company Limited
BioCryst Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
Pharming Group N.V.
CSL Limited
Attune Pharmaceuticals, Inc.
These companies focus on research and development of novel therapies, strategic partnerships, and expanding their global presence to address unmet needs in the HAE therapeutic space.
Uncover More Reports
About Us:
Expert Market Research is a leading market research firm delivering data-driven insights to the pharmaceutical, biotechnology, and medical device industries. Our comprehensive research solutions include market research reports, providing in-depth analysis of industry trends and competitive landscapes; drug pipeline reports, tracking drug development progress, clinical trials, and regulatory approvals; epidemiology reports, offering detailed disease prevalence and patient population studies; and patent reports, assessing intellectual property landscapes and innovation trends, among others.
Leveraging proprietary data, advanced analytics, and expert methodologies, we help businesses navigate complex markets, optimize strategies, and drive innovation. We empower clients with actionable intelligence, enabling them to make informed decisions and stay ahead in the rapidly evolving healthcare sector.
Media Contact:
Company Name: Claight Corporation
Contact Person: Roshan Kumar, Digital Marketing
Email: sales@expertmarketresearch.com
Toll-Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA
Website: www.expertmarketresearch.com
